Get started

Travere Therapeutics, Inc.

No trades
See on Supercharts
Overview
News Ideas Financials Technicals Forecast

TVTX chart

Key stats

Market capitalization
649.26MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.40USD
Net income
−278.482MUSD
Revenue
212.018MUSD
Shares float
70.993M
Beta
1.61

About Travere Therapeutics, Inc.

Sector
Health Technology
CEO
Eric M. Dube
Headquarters
San Diego
Website
travere.com
Employees (FY)
462
Founded
2008
ISIN
US89422G1076
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

News Flow

Keep readingKeep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Financials

Performance
Revenue to profit conversion
Earnings
Next:—
‪0‬

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
TradeStation
TradeStation
Featured
Stocks, Crypto, Futures
4.4Very Good
Learn more
Interactive Brokers
Interactive Brokers
Stocks, Futures, Bonds
4.4Very Good
Learn more

See all brokers